Login / Signup

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.

R Brett McQueenSeth J BaumMichael J LouieWilliam J SasielaAikaterini BilitouHemal ShahBeth NashKristin K GillardKausik K Ray
Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
Further LDL-C reductions through the addition of BA+EZE FDC to maximally tolerated statins are predicted to reduce major adverse cardiovascular events compared with the addition of EZE. Benefits are potentially greater among those with higher starting LDL-C.
Keyphrases
  • cardiovascular events
  • cardiovascular disease
  • low density lipoprotein
  • cardiovascular risk factors
  • type diabetes
  • coronary artery disease
  • human health
  • metabolic syndrome
  • adverse drug